Bridgeway Capital Management LLC Raises Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Bridgeway Capital Management LLC grew its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 12.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 146,500 shares of the company’s stock after acquiring an additional 16,500 shares during the period. Bridgeway Capital Management LLC owned about 0.21% of Amylyx Pharmaceuticals worth $554,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. increased its holdings in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after purchasing an additional 4,883 shares during the period. XTX Topco Ltd grew its position in shares of Amylyx Pharmaceuticals by 12.0% during the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock worth $202,000 after buying an additional 5,704 shares in the last quarter. Northern Trust Corp grew its position in shares of Amylyx Pharmaceuticals by 11.8% during the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock worth $403,000 after buying an additional 11,214 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. Finally, Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Up 0.7%

Shares of Amylyx Pharmaceuticals stock opened at $4.61 on Monday. The company has a market cap of $410.68 million, a P/E ratio of -1.21 and a beta of -0.60. The firm’s 50 day moving average price is $4.04 and its 200-day moving average price is $4.22. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.03. As a group, equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 12,425 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $43,114.75. Following the transaction, the insider now owns 194,375 shares in the company, valued at $674,481.25. This represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $74,570.30. Following the completion of the transaction, the chief executive officer now directly owns 3,355,280 shares of the company’s stock, valued at $11,642,821.60. The trade was a 0.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,980 shares of company stock valued at $168,627 in the last quarter. 11.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

AMLX has been the topic of several recent research reports. HC Wainwright increased their target price on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 6th. Mizuho raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $3.00 to $7.00 in a report on Monday, April 7th. Finally, Leerink Partners raised shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $4.00 to $10.00 in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and an average price target of $9.67.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.